REFERENCES
1. Centers for Disease Control and Prevention. HIV Surveillance Report,
2016; vol. 28.http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
Published November 2017. Accessed February 15, 2018.
2. Centers for Disease Control and Prevention (CDC) Estimates of new HIV
infections in the United States.https://www.cdc.gov/nchhstp/newsroom/docs/fact-sheet-on-hiv-estimates.pdf.
Accessed 15 February 2018.
3. Zaidi J, Grapsa E, Tanser F, Newell ML and Bärnighausen T. Dramatic
increases in HIV prevalence after scale-up of antiretroviral treatment:
a longitudinal population-based HIV surveillance study in rural
kwazulu-natal. AIDS (London, England) . 2013;27:2301-5.
4. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM,
Huebner RE, Janoff EN, Justice AC, Kuritzkes D, Nayfield SG, Plaeger SF,
Schmader KE, Ashworth JR, Campanelli C, Clayton CP, Rada B, Woolard NF
and High KP. Aging and infectious diseases: workshop on HIV infection
and aging: what is known and future research directions. Clinical
infectious diseases : an official publication of the Infectious Diseases
Society of America . 2008;47:542-53.
5. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P,
Arveiler D, Ruidavets JB, Reynes J, Bingham A and Raffi F. Risk factors
for coronary heart disease in patients treated for human
immunodeficiency virus infection compared with the general population.Clinical infectious diseases : an official publication of the
Infectious Diseases Society of America . 2003;37:292-8.
6. De Castro S, d’Amati G, Gallo P, Cartoni D, Santopadre P, Vullo V,
Cirelli A and Migliau G. Frequency of development of acute global left
ventricular dysfunction in human immunodeficiency virus infection.Journal of the American College of Cardiology . 1994;24:1018-24.
7. Gopal M, Bhaskaran A, Khalife WI and Barbagelata A. Heart Disease in
Patients with HIV/AIDS-An Emerging Clinical Problem. Current
Cardiology Reviews . 2009;5:149-54.
8. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W,
Thiebaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A and Lundgren
JD. Class of antiretroviral drugs and the risk of myocardial infarction.The New England journal of medicine . 2007;356:1723-35.
9. Zanetti HR, Mendes EL, Palandri Chagas AC, Gomes Douglas MO, Paranhos
Lopes LT, Roever L, Goncalves A and Santos Resende E. Triad of the
Ischemic Cardiovascular Disease in People Living with HIV? Association
Between Risk Factors, HIV Infection, and Use of Antiretroviral Therapy.Current atherosclerosis reports . 2018;20:30.
10. Hsu JC, Li Y, Marcus GM, Hsue PY, Scherzer R, Grunfeld C and Shlipak
MG. Atrial Fibrillation and Atrial Flutter in Human Immunodeficiency
Virus-Infected Persons: Incidence, Risk Factors, and Association With
Markers of HIV Disease Severity. Journal of the American College
of Cardiology . 2013;61:2288-2295.
11. Tseng ZH, Secemsky EA, Dowdy D, Vittinghoff E, Moyers B, Wong JK,
Havlir DV and Hsue PY. Sudden cardiac death in patients with human
immunodeficiency virus infection. Journal of the American College
of Cardiology . 2012;59:1891-6.
12. Databases H. Healthcare Cost and Utilization Project (HCUP).
December 2016. Agency for
Healthcare Research and Quality, Rockville, MD.www.hcup-us.ahrq.gov/nisoverview.jsp.
Accessed Febraury 18, 2018.
13. Steiner C, Elixhauser A and Schnaier J. The healthcare cost and
utilization project: an overview. Effective clinical practice :
ECP . 2002;5:143-51.
14. Deshmukh A, Kumar G, Kumar N, Nanchal R, Gobal F, Sakhuja A and
Mehta JL. Effect of Joint National Committee VII report on
hospitalizations for hypertensive emergencies in the United States.The American journal of cardiology . 2011;108:1277-82.
15. Lahewala S, Arora S, Patel P, Kumar V, Patel N, Tripathi B, Patel N,
Kallur KR, Shah H, Syed A, Gidwani U, Viles-Gonzalez JF and Deshmukh A.
Atrial fibrillation: Utility of CHADS2 and CHA2DS2-VASc scores as
predictors of readmission, mortality and resource utilization.International journal of cardiology . 2017;245:162-167.
16. Tripathi B, Arora S, Mishra A, Kundoor VR, Lahewala S, Kumar V, Shah
M, Lakhani D, Shah H, Patel NV, Patel NJ, Dave M, Deshmukh A, Sudhakar S
and Gopalan R. Short-term outcomes of atrial flutter ablation.Journal of cardiovascular electrophysiology . 2017;28:1275-1284.
17. State and County QuickFacts - U.S. Census Bureau;https://www.census.gov/research/.
Accessed Febraury 18, 2018.
18. Singh V, Badheka AO, Patel SV, Patel NJ, Thakkar B, Patel N, Arora
S, Patel N, Patel A, Savani C, Ghatak A, Panaich SS, Jhamnani S,
Deshmukh A, Chothani A, Sonani R, Patel A, Bhatt P, Dave A, Bhimani R,
Mohamad T, Grines C, Cleman M, Forrest JK and Mangi A. Comparison of
Inhospital Outcomes of Surgical Aortic Valve Replacement in Hospitals
With and Without Availability of a Transcatheter Aortic Valve
Implantation Program (from a Nationally Representative Database).The American journal of cardiology . 2015;116:1229-36.
19. Patel NJ, Deshmukh A, Pant S, Singh V, Patel N, Arora S, Shah N,
Chothani A, Savani GT, Mehta K, Parikh V, Rathod A, Badheka AO, Lafferty
J, Kowalski M, Mehta JL, Mitrani RD, Viles-Gonzalez JF and Paydak H.
Contemporary trends of hospitalization for atrial fibrillation in the
United States, 2000 through 2010: implications for healthcare planning.Circulation . 2014;129:2371-9.
20. Software HEC. Healthcare Cost and Utilization Project (HCUP).
February 2017. Agency for Healthcare Research and Quality, Rockville,MD.
2017;https://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp.
Accessed Febraury 17, 2018.
21. Armitage P. Tests for Linear Trends in Proportions and Frequencies.Biometrics . 1955;11:375-386.
22. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F,
Francioli P, D’Arminio Monforte A, Fox Z and Lundgren JD. Changes in the
cause of death among HIV positive subjects across Europe: results from
the EuroSIDA study. AIDS (London, England) . 2002;16:1663-71.
23. Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S,
Blaxhult A, Phillips AN and Lundgren J. Causes of death in HIV
infection: the key determinant to define the clinical response to
anti-HIV therapy. AIDS (London, England) . 2004;18:2333-7.
24. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D,
Jougla E, Semaille C, Morlat P, Salmon D, Cacoub P and Chene G. Changes
in causes of death among adults infected by HIV between 2000 and 2005:
The ”Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic).Journal of acquired immune deficiency syndromes (1999) .
2008;48:590-8.
25. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML,
Tien PC, Shlipak MG, Sidney S, Polak JF, O’Leary D, Bacchetti P and
Kronmal RA. Preclinical atherosclerosis due to HIV infection: carotid
intima-medial thickness measurements from the FRAM study. AIDS
(London, England) . 2009;23:1841-9.
26. Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK and Triant VA.
Comparison of ischemic stroke incidence in HIV-infected and
non-HIV-infected patients in a US health care system. Journal of
acquired immune deficiency syndromes (1999) . 2012;60:351-8.
27. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju
P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS and Chung
MK. Inflammation as a Risk Factor for Atrial Fibrillation.Circulation . 2003;108:3006-3010.
28. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA,
Bauer JA, Tchou PJ, Niebauer MJ, Natale A and Van Wagoner DR. C-reactive
protein elevation in patients with atrial arrhythmias: inflammatory
mechanisms and persistence of atrial fibrillation. Circulation .
2001;104:2886-91.
29. Deeks SG. HIV Infection, Inflammation, Immunosenescence, and Aging.Annual review of medicine . 2011;62:141-55.
30. Hu Y-F, Chen Y-J, Lin Y-J and Chen S-A. Inflammation and the
pathogenesis of atrial fibrillation. Nature Reviews Cardiology .
2015;12:230.
31. Samaras K, Wand H, Law M, Emery S, Cooper D and Carr A. Prevalence
of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active
Antiretroviral Therapy Using International Diabetes Foundation and Adult
Treatment Panel III Criteria. Diabetes Care . 2007;30:113.
32. Sani MU and Okeahialam BN. QTc interval prolongation in patients
with HIV and AIDS. Journal of the National Medical Association .
2005;97:1657-61.
33. Anson BD, Weaver JGR, Ackerman MJ, Akinsete O, Henry K, January CT
and Badley AD. Blockade of HERG channels by HIV protease inhibitors.The Lancet . 2005;365:682-686.
34. Kocheril AG, Bokhari SA, Batsford WP and Sinusas AJ. Long QTc and
torsades de pointes in human immunodeficiency virus disease.Pacing and clinical electrophysiology : PACE . 1997;20:2810-6.
35. Kroll CR and Gettes LS. T wave alternans and Torsades de Pointes
after the use of intravenous pentamidine. Journal of
cardiovascular electrophysiology . 2002;13:936-8.
36. Khera R, Angraal S, Couch T, Welsh JW, Nallamothu BK, Girotra S,
Chan PS and Krumholz HM. Adherence to Methodological Standards in
Research Using the National Inpatient Sample. Jama .
2017;318:2011-2018.